Founded in 2021, Hangzhou SINODO Pharmaceutical Technology Co., Ltd. is an innovative biotechnology enterprise in the peptide field. Located in Hangzhou Medicine Port Town, the company relies on the rich biomedical resources and industrial ecology in the region, and takes “integration of research, production and marketing” as the core of its strategy to promote the innovative development and value upgrading of peptide drug industry.

Since its establishment, the company has built up three core business segments with its forward-looking strategic layout and solid professional ability: peptide API and customized peptide service, which provides global customers with high-purity and high-stability peptide raw materials and personalized customized solutions; peptide pharmacological development and research service (CRO), which relies on the professional R&D team and advanced technological platforms to provide customers with full-process technical support from early drug discovery to preclinical research; and peptide pharmaceutical development service (CRO), which relies on professional R&D teams and advanced technological platforms to provide customers with full-process technical support from early drug discovery to clinical research. CRO provides customers with full-process technical support from early drug discovery to preclinical research; and customized manufacturing service (CDMO) for peptide raw materials and peptide products, which realizes efficient transformation from laboratory to industrialization with excellent process development and production capacity, and meets diversified production needs of customers.

The company has gathered nearly 100 professional R&D and production elites, of which more than 90% have bachelor's degree or above. The team has always stood at the forefront of peptide R&D and production technology, with a deep understanding of international drug regulations and close tracking of the latest global technological developments, and possesses the international leading level of peptide drug design and R&D strength, successfully leading a number of peptide projects to complete the filing of the approval, and driving the development of the industry with innovation. Our core researchers have more than 20 years of experience in the peptide industry, and have achieved outstanding results in product development and industrialization, which ensures that our technological achievements can be efficiently transformed into actual productivity.

With continuous technological innovation and strict quality management, the company has obtained many honors and qualifications, such as ISO9001 quality management system certification, certification of science and technology-based small and medium-sized enterprises in Zhejiang Province, awarding of Hangzhou High-tech Research and Development Center, designation of specialized, special and new small and medium-sized enterprises in Zhejiang Province, and certification of National High-tech Enterprises, etc. These achievements are not only a testament to the company's strength. These achievements are not only the authoritative recognition of the company's strength, but also a solid guarantee that we continue to create value for customers and promote the progress of the industry.

In the future, Sinodis will continue to uphold the development concept of innovation-driven, quality-first, and continuously improve its core competitiveness to provide global customers with better peptide products and services, and contribute to the development of the peptide drug industry.